Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.